Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 6, 2000, Pages 759-766

  Ammon, S ^a,b   Treiber, G ^a   Kees, F ^c   Klotz, U ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CREATININE; LANSOPRAZOLE; METRONIDAZOLE; RANITIDINE;

ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE CLEARANCE; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STEADY STATE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGE FACTORS; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; CREATININE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KIDNEY; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; RANITIDINE;

EID: 0034129266     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00756.x     Document Type: Article

References (32)

1. 1 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5.
2. 2 Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
3. 3 Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
4. 4 McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996; 110: 926-38.
5. 5 Soll AH. Medical treatment of peptic ulcer disease. Practice guidelines. Practical Parameters Committee of the American College of Gastroenterology. J Am Med Assoc 1996; 275: 622-9.
6. 6 European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Conference Report. Gut 1997; 41: 8-13.
7. 7 Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 98: 2330-8.
8. 8 Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost effectiveness analysis. Am J Gastroenterol 1996; 91: 246-57.
9. 9 Williamson R, Pipkin GA, Wood JR. New options in Helicobacter pylori eradication. Efficacy, resistance and synergy. Scand J Gastroenterol 1998; 33: 36-40.
10. 10 Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-20.
11. 11 Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short term quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-8.
12. 12 Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994; 29: 1070-5.
13. 13 Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther 1997; 11: 711-8.
14. 14 Treiber G, Ammon S, Klotz U. 5-day H. pylori eradication. Aliment Pharmacol Ther 1999; 13: 1252.
15. 15 Treiber G, Ammon S, Wittig J, Walker S, Klotz U. The impact of clinical factors on the outcome of a new short term H. pylori eradication scheme. Gut 1999; 45(Suppl. 111): A117(Abstract).
16. 16 Boutagy J, More DG, Munro IA, Shenfield GM. Simultaneous analysis of cimetidine and ranitidine in human plasma by HPLC. J Liquid Chromatogr 1984; 7: 1651-64.
17. 17 Jessa MJ, Barrett DA, Shaw PN, Spiler RC. Rapid and selective high-performance liquid chromatographic method for the determination of metronidazole and its active metabolite in human plasma, saliva and gastric juice. J Chromatogr B 1996; 67: 374-8.
18. 18 Kees F. Preparation for HPLC of samples in biological matrices, and problems of degradation. In: Reeves DS, Ullman U, eds. High-Performance Liquid Chromatography in Medical Microbiology. Progress in Microbiology, Vol 2. Stuttgart, Germany: G. Fischer-Verlag, 1986: 7-19.
19. 19 Kees F, Spangler S, Wellenhofer M. Determination of macrolides in biological matrices by high-performance liquid chromatography with electrochemical detection. J Chromatogr A 1998; 812: 287-93.
20. 20 Fliser D, Franck E, Joest M, et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Internat 1997; 51: 1196-204.
21. 21 Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243-70.
22. 22 Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328-64.
23. 23 Sjövall J, Alvan G, Huitfeldt B. Intra-and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. Br J Clin Pharmacol 1986; 21: 171-81.
24. 24 Grant SM, Langtry HD, Brodgen RN. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 37: 801-70.
25. 25 Chu SY, Wilson DS, Guay DR, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992; 32: 1045-9.
26. 26 Hussein Z, Grannemann GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 3.
27. 27 Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9.
28. 28 Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36: 425-38.
29. 29 Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
30. 30 Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-83.
31. 31 Goddard AF, Jessa MJ, Berret DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-67.
32. 32 Markham A, McTavish D. Clarithromycin and omepranole as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs 1996; 51: 161-78.